These antagonistic effects of GSK3α inhibition on glioma or neuroblastoma cell viability indicate the need to understand the cellular background to identify the inhibition of GSK3α as a therapeutic candidate against cancer of the nervous system. Here, GSK3A is linked to central nervous system cancer.